# Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

> **NCT03009045** · PHASE2 · COMPLETED · sponsor: **Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center** · enrollment: 44 (actual)

## Conditions studied

- Bone and Joint Infection

## Interventions

- **DRUG:** Tedizolid

## Key facts

- **NCT ID:** NCT03009045
- **Lead sponsor:** Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-06
- **Primary completion:** 2021-03-23
- **Final completion:** 2021-08-06
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03009045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03009045, "Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03009045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*